Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Update

Barinthus Biotherapeutics plc (NASDAQ:BRNS) saw a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 8,400 shares, an increase of 110.0% from the October 15th total of 4,000 shares. Based on an average daily volume of 29,500 shares, the short-interest ratio is presently 0.3 days. Approximately 0.0% of the shares of the stock are sold short.

Barinthus Biotherapeutics Stock Down 29.7 %

BRNS traded down $0.41 during midday trading on Friday, hitting $0.97. The company had a trading volume of 263,301 shares, compared to its average volume of 24,928. The stock’s 50 day moving average price is $1.30 and its 200 day moving average price is $1.54. The company has a market capitalization of $38.36 million, a price-to-earnings ratio of -0.64 and a beta of -0.59. Barinthus Biotherapeutics has a 52 week low of $0.88 and a 52 week high of $4.16.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.23. The business had revenue of $14.97 million during the quarter. During the same quarter last year, the business earned ($0.37) earnings per share. Research analysts predict that Barinthus Biotherapeutics will post -1.52 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Catalina Capital Group LLC bought a new position in Barinthus Biotherapeutics during the 2nd quarter valued at $25,000. Ipswich Investment Management Co. Inc. bought a new stake in Barinthus Biotherapeutics in the 2nd quarter worth about $32,000. BlueCrest Capital Management Ltd purchased a new stake in Barinthus Biotherapeutics in the 1st quarter valued at about $1,292,000. DC Funds LP bought a new position in shares of Barinthus Biotherapeutics during the 1st quarter worth approximately $1,528,000. Finally, Alphabet Inc. bought a new position in shares of Barinthus Biotherapeutics in the second quarter valued at approximately $2,119,000. Hedge funds and other institutional investors own 25.20% of the company’s stock.

Wall Street Analyst Weigh In

BRNS has been the subject of a number of research reports. Alliance Global Partners dropped their target price on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating for the company in a report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Barinthus Biotherapeutics in a research report on Friday, November 8th.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.